Clin Endosc.  2024 Nov;57(6):763-764. 10.5946/ce.2024.273.

Risk of Barrett’s esophagus progression to esophageal adenocarcinoma

• Kota L
• Tyberg A

• KMID: 2561158
• DOI: http://doi.org/10.5946/ce.2024.273

Reference

1. Whiteman DC, Appleyard M, Bahin FF, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2015; 30:804–820.

2. American Cancer Society (ACS). Cancer facts & figures 2024. ACS; 2024.

3. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011; 365:1375–1383.

4. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002; 122:26–33.

5. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022; 117:559–587.

6. Rubenstein JH, Sawas T, Wani S, et al. AGA clinical practice guideline on endoscopic eradication therapy of Barrett's esophagus and related neoplasia. Gastroenterology. 2024; 166:1020–1055.

7. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014; 63:7–42.

8. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017; 49:191–198.

9. Elbe P, Öst Å, Mellbom L, et al. Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden. Clin Endosc. 2024; 57:768–774.

10. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020; 91:3–10.